GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Modus Therapeutics Holding AB (FRA:99Z) » Definitions » Short Interest

Modus Therapeutics Holding AB (FRA:99Z) Short Interest


View and export this data going back to 2021. Start your Free Trial

What is Modus Therapeutics Holding AB Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Modus Therapeutics Holding AB's Short Interest

For the Biotechnology subindustry, Modus Therapeutics Holding AB's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Modus Therapeutics Holding AB's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Modus Therapeutics Holding AB's Short Interest distribution charts can be found below:

* The bar in red indicates where Modus Therapeutics Holding AB's Short Interest falls into.


;
;

Modus Therapeutics Holding AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Modus Therapeutics Holding AB (FRA:99Z) » Definitions » Short Interest
Comparable Companies
OSTO:SPRINT OSTO:COMBI XSAT:NIDHOG OSTO:EXPRS2 OSTO:ONCOZ XSAT:CHOSA OSTO:ACOU OSTO:CMOTEC B XSAT:RESP XSAT:PHAL VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
MODTX:Sweden
Address
Olof Palmes gata 29 IV, Stockholm, SWE, 111 22
Website
https://www.modustx.com
Modus Therapeutics Holding AB is a Swedish clinical biotechnology company developing a treatment for sepsis, endotoxemia, severe malaria, and other disorders with severe systemic inflammation as well as states of anemia, related to chronic inflammation such as kidney diseases through its patented polysaccharide sevuparin. The drug candidate sevuparin has the opportunity to benefit patients and save large healthcare costs.

Modus Therapeutics Holding AB Headlines

No Headlines